

COPY

SHEET 1 OF 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067 004A	APPLICATION NO 10/000,439
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Saxon	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE October 24, 2001	GROUP Not yet assigned

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
1.	Bielekova, B. et al., "Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand," <i>Nature Medicine</i> , Vol. 6, No. 10, pp. 1167-1175 (2000).	
2.	Bridges, Jr., S. L. et al., "T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis," <i>Emerging Therapies for Rheumatoid Arthritis</i> , Vol. 24, No. 3, pp. 641-650 (1998).	
3.	Chaillous, L. et al., "Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM," <i>Diabetologia</i> , Vol. 37, pp. 491-499 (1994).	
4.	Delespesse, G. et al., "The Low-Affinity Receptor for IgE," <i>Immunological Reviews</i> , No. 125, pp. 77-97 (1992).	
5.	Dombrowicz, D. et al., "Anaphylaxis Mediated Through a Humanized High Affinity IgE Receptor," <i>The Journal of Immunology</i> , Vol. 157, pp. 1645-1651 (1996).	
6.	Gold, D. P. et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <i>Critical Reviews in Immunology</i> , Vol. 17, pp. 507-510 (1997).	
7.	Kaplan, "Urticaria and Angioedema," <i>Inflammation: Basic Principles and Clinical Correlates</i> , (Gallin and Snyderman Eds.), Chapter 35: 667-678 Raven Press, NY (1988).	
8.	Kappos et al., "Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial," <i>Nature Medicine</i> , Vol. 6, No. 10, pp. 1176-1182 (2000).	
9.	Kisselev, A. F. et al., "Proteasome Active Sites Allosterically Regulate Each Other, Suggesting a Cyclical Bite-Chew Mechanism for Protein Breakdown," <i>Molecular Cell</i> , Vol. 4, pp. 395-402 (1999).	
10.	McFarland, H. F., "Complexities in the Treatment of Autoimmune Disease," <i>Science</i> , Vol. 274, pp. 2037-2038 (1996).	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

# COPY

SHEET 2 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Saxon
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE October 24, 2001
		GROUP Not yet assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
11	Moreland, L. W. et al., "V $\beta$ 17 T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis: Results of Phase I Dose Escalation Study," <u>The Journal of Rheumatology</u> , pp. 1353-1362 (1996).
12	Nepom, G. T., "Glutamic acid decarboxylase and other autoantigens," <u>Current Opinion in Immunology</u> , Vol. 7, pp. 825-830 (1995).
13	Pamer, E. et al., "Mechanisms of MHC Class I-Restricted Antigen Processing," <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 323-358 (1998).
14	Phillips, N. E. et al., "Cross-Linking of B Lymphocyte Fc $\gamma$ Receptors and Membrane Immunoglobulin Inhibits Anti-Immunoglobulin-Induced Blastogenesis," <u>The Journal of Immunology</u> , Vol. 132, No. 2, pp. 627-632 (1984).
15	Spack, E. G. et al., "Induction of Tolerance in Experimental Autoimmune Myasthenia Gravis with Solubilized MHC Class II:Acetylcholine Receptor Peptide Complexes," <u>Journal of Autoimmunity</u> , Vol. 8, pp. 787-807 (1995).
16	TePas, E. C. et al., "Immunotherapy of asthma and allergic diseases," <u>Current Opinion in Pediatrics</u> , Vol. 12, pp. 574-578 (2000).
17	Tunon, J. M., "Immunoglobulines E et cellules de l'inflammation," <u>Rev. Mal. Resp.</u> , Vol. 13, pp. 27-36 (1996).
18	Weiner, H. L., <u>Science</u> , 259(5099):1321-1324 (1993).
19	Yodoi, J. et al., "Low affinity IgE receptors: regulation and functional roles in cell activation," <u>1989 IgE, Mast Cells and the Allergic Response</u> . Wiley, Chichester (Ciba Foundation Symposium 147) pp. 133-153.
20	Yoon, Ji-Won et al., "Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in $\beta$ Cells," <u>Science</u> , Vol. 284, pp. 1183-1187 (1999).

W:\DOCS\IED\JD-1060.DOC\031902

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	